日本女性人乳头瘤病毒从感染到宫颈癌的基因型流行率与年龄分布:系统综述与荟萃分析
日本HPV疫苗接种覆盖率不足合格人群的1%,宫颈癌发病与死亡上升;本系统综述与荟萃分析检索至2021年3月的英文和日文数据库,按疾病阶段汇总日本女性细胞学和组织学样本的HPV基因型流行率。任何HPV基因型在细胞学正常女性中汇总估计为15.6%(95%CI 12.3-19.4),在浸润性宫颈癌(ICC)中为85.6%(80.7-89.8);ICC中九价疫苗基因型汇总流行率为71.5%(64.9-77.6),HPV阳性ICC中超过90%的感染可由九价疫苗预防。作者认为九价疫苗可能对降低日本宫颈癌发病和死亡影响最大。
要点
- 细胞学正常女性任何HPV基因型汇总流行率为15.6%(95%CI 12.3-19.4)。
- ICC中任何HPV基因型汇总流行率为85.6%(95%CI 80.7-89.8)。
- ICC中九价疫苗基因型汇总流行率为71.5%(95%CI 64.9-77.6)。
核心结论
- 日本女性HPV流行率高,九价疫苗可能对降低日本宫颈癌发病和死亡影响最大。
研究设计与样本
- 系统综述与荟萃分析,检索英文和日文数据库至2021年3月,纳入报告日本女性细胞学和histology样本HPV基因型的研究,按疾病阶段计算汇总估计,采用随机效应荟萃分析,PROSPERO注册号CRD42018117596。
主要发现
- 细胞学正常女性57759例中任何HPV基因型汇总估计为15.6%(95%CI 12.3-19.4),ICC 4306例中为85.6%(80.7-89.8)。
- HR-HPV在细胞学HSIL中汇总流行率为86.0%(95%CI 73.9-94.9),组织学CIN3/AIS中为76.9%(52.1-94.7),ICC中为75.7%(68.0-82.6)。
- ICC中二价疫苗基因型汇总流行率为58.5%(95%CI 52.1-64.9),四价疫苗基因型为58.6%(52.2-64.9),九价疫苗基因型为71.5%(64.9-77.6)。
- HPV阳性ICC中超过90%的感染可由九价疫苗预防。
- 所有HPV汇总估计均存在 considerable 异质性,ICC的异质性无法由研究设计、样本类型、HPV检测类型或HPV DNA检测方法的变异解释,但1990年代发表的研究任何HPV和HR HPV基因型流行率估计较低。
局限性
- 所有HPV汇总估计均存在 considerable 异质性。
- ICC的异质性无法由研究设计、样本类型、HPV检测类型或HPV DNA检测方法的变异解释。
- 1990年代发表的研究任何HPV和HR HPV基因型流行率估计较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: National HPV vaccination coverage in Japan is less than one percent of the eligible population and cervical cancer incidence and mortality are increasing. This systematic review and meta-analysis aimed to provide a comprehensive estimate of HPV genotype prevalence for Japan. METHODS: English and Japanese databases were searched to March 2021 for research reporting HPV genotypes in cytology and histology samples from Japanese women. Summary estimates were calculated by disease stage from cytology only assessment - Normal, ASCUS, LSIL, HSIL and from histological assessment - CIN1, CIN2, CIN3/AIS, ICC (ICC-SCC, and ICC-ADC), and other. A random-effects meta-analysis was used to calculate summary prevalence estimates of any-HPV, high-risk (HR) and low-risk (LR) vaccine types, and vaccine genotypes (bivalent, quadrivalent, or nonavalent). This study was registered with PROSPERO: CRD42018117596. RESULTS: A total of 57759 women with normal cytology, 1766 ASCUS, 3764 LSIL, 2017 HSIL, 3130 CIN1, 1219 CIN2, 869 CIN3/AIS, and 4306 ICC (which included 1032 ICC-SCC, and 638 ICC-ADC) were tested for HPV. The summary estimate of any-HPV genotype in women with normal cytology was 15·6% (95% CI: 12·3-19·4) and in invasive cervical cancer (ICC) was 85·6% (80·7-89·8). The prevalence of HR-HPV was 86·0% (95% CI: 73·9-94·9) for cytological cases of HSIL, 76·9% (52·1-94·7) for histological cases of CIN3/AIS, and 75·7% (68·0-82·6) for ICC. In women with ICC, the summary prevalence of bivalent vaccine genotypes was 58·5% (95% CI: 52·1-64·9), for quadrivalent genotypes was 58·6% (52·2-64·9) and for nonavalent genotypes was 71·5% (64·9-77·6), and of ICC cases that were HPV positive over 90% of infections are nonavalent vaccine preventable. There was considerable heterogeneity in all HPV summary estimates and for ICC, this heterogeneity was not explained by variability in study design, sample type, HPV assay type, or HPV DNA detection method, although studies published in the 1990s had lower prevalence estimates of any-HPV and HR HPV genotypes. INTERPRETATIONS: HPV prevalence is high among Japanese women. The nonavalent vaccine is likely to have the greatest impact on reducing cervical cancer incidence and mortality in Japan.
引用
- Palmer M, Katanoda K, Saito E, et al. Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis. Vaccine. 2022. PMID: 36085257. doi:10.1016/j.vaccine.2022.07.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。